Shares of the creator of the anti-aging drug Telomir are down 47%. Why does Zacks believe in them?

Zacks Small-Cap Research advises investors to pay attention to the micro-cap securities of Telomir Pharmaceuticals. The drug it is working on has the potential to slow aging, and this opens up virtually unlimited market potential, the analysts explain. 

Investors should pay attention to shares of Telomir Pharmaceuticals, a biotech company with a capitalization of $65 million, before it starts testing its drug candidate on humans, according to Zacks SCR. Analysts at set a $15.5 target price for Telomir's securities, which is seven times the current quote. On Friday, July 25, the company's stock closed trading at $2.19. The stock is now trading 47% cheaper than it was at the beginning of the year;

Telomir is developing therapies that address the root causes of biological aging and age-related diseases, such as Alzheimer's or Parkinson's disease. 

Its lead drug candidate is called Telomir-1. It, the company claims, protects telomeres - sections of chromosomes that under normal circumstances shorten with age. This process, along with a reaction to metals, precisely increases the risk of age-related diseases, Telomir explains. 

In preclinical animal studies, the drug candidate has already demonstrated the ability to "reverse biological aging," writes Zacks SCR. Last week, for example, Telomir reported last week that the tests were able to restore the function of mitochondria - which are found inside cells and are responsible for the energy production necessary for its life. This is an encouraging signal for programs targeting neurodegenerative diseases whose progression is driven by mitochondrial dysfunction, such as Parkinson's disease, said Raphael Mayer, CEO of Smart Assays, which specializes in conducting preclinical research under contract to drug developers. 

The results could be relevant to other ailments, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Werner syndrome and progeria, a rare genetic disease that leads to premature aging, Zacks SCR writes. So far, for example, the US regulator has approved only one therapy for progeria, which increases life expectancy by an average of 4.3 years, but does not eliminate the pathology, the analysts add. 

Telomir-1 has the potential to slow aging, eliminate the effects of various age-related diseases, dramatically changing the lives of millions of patients, the analysts write. And this opens up virtually unlimited market potential, they summarize.

This article was AI-translated and verified by a human editor